|
|
Post by tarheelblue004 on Dec 26, 2017 19:45:25 GMT -5
I know my acct is full of freshly acquired calls and I would love a reason to trade them before the new year. ^your username and actions line up  |
|
|
|
Post by babaoriley on Dec 26, 2017 20:31:24 GMT -5
The last time Mike C was nearing an important financial point in time, he handled it far better than anyone anticipated. I don't see this debt payment as being extraordinarily significant meaning I expect Mike C already knows how it's going to play out. Do you expect this January 15th debt resolution to be a catalyst event that will move the stock significantly up or down? If so, which direction? BTW, I appreciate all your posts. The option buyer is betting that the price will be manipulated over the $3.25 cut-off point so his $3.00 calls will be in the money. I'm not certain that is a sure thing - Mike has enough shares on the shelf to settle with Deerfield and swallow the dilution. That said, the Jan 19 $3.00 calls are sitting at 9c and I am seriously tempted to to take a position on a lottery ticket basis - if it came off I would double my money. My guess is that you are seeing others place the same bet. Mannkind need to preserve cash so they want Deerfield to take shares and for that they need the price over $3.25. Regardless of his age, hippie makes some great points! |
|
|
|
Post by babaoriley on Dec 26, 2017 20:34:26 GMT -5
Option traders rarely buy or sell naked options; they have some other security in the portfolio and use options to hedge a movement one way or another. When you see option volumes spike, even if they seem to be out of the money, they might just be closing out a position to lock in the profit as of today. Few option contracts are ever exercised; most are sold back to the market, or two off-setting contracts are allowed to cancel each other out. When you look at the option market, you only have half the story and there is no way to know what the rest of the story looks like. Wrong Matt, I and many others do just that; however, if you had qualified your statement by just prefixing the bolded language with the single word "Successful," I would have had no beef with you.  |
|
|
|
Post by drman7 on Dec 26, 2017 20:58:27 GMT -5
Here is what we know : MannKind will start the year with $46 million which includes the $10 million in escrow for the January 15th payment. MannKind is burning approximately $24 million a quarter. A Deerfield covenant require MannKind to maintain $25 at the end of the quarter. Assuming MannKind pays Deerfield $10 million from the escrow account, that forces cash to dwindle to $12 by the end of Q1; violating the covenant. MannKind needs a partnership with substantial upfront $, dilute, or a combination of both. Why wouldn’t they move it again so we would not be in violation of it? I still think there will be a sit significant announcement on 1/2/18 |
|
|
|
Post by dreamboatcruise on Jan 2, 2018 15:23:50 GMT -5
Why wouldn’t they move it again so we would not be in violation of it? I still think there will be a sit significant announcement on 1/2/18 Before or after close of market? |
|
|
|
Post by Clement on Jan 2, 2018 17:07:13 GMT -5
Maybe an announcement 30 days after Tross' stock purchase of Dec.21?
|
|
|
|
Post by brotherm1 on Jan 4, 2018 19:43:22 GMT -5
|
|
|
|
Post by dreamboatcruise on Jan 4, 2018 19:50:29 GMT -5
There's always some company announcing something significant. Probably were some significant announcements even 2 days ago... and yesterday. |
|
|
|
Post by akemp3000 on Jan 4, 2018 20:09:59 GMT -5
Significant and more importantly relevant to MNKD. This is good.
|
|
|
|
Post by agedhippie on Jan 5, 2018 3:36:16 GMT -5
Significant and more importantly relevant to MNKD. This is good. There is no way that PR moves Mannkind's share price! For a start approval was granted three months ago and the PR makes no link at all to Afrezza. It is a good example of the use of PRs to keep a product visible (free advertising) - we would do well to follow suit. |
|
|
|
Post by letitride on Jan 5, 2018 4:21:28 GMT -5
That Abbott effectively markets its CGM is paramount to Afrezza marketing. If you want timely fast acting response from your insulin therapy you need to know when to respond. The Libre isn't perfect but it is a big step in the right direction and you could say the same for Afrezza . Together well time will tell.
|
|
